PS
VRDN icon

Principal Securities’s Viridian Therapeutics VRDN Stock Holding History

Principal Securities’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$194 – 3452
2025
Q3 		$194 Hold
9
– – ﹤0.01% 3652
2025
Q2 		$126 Hold
9
– – ﹤0.01% 3633
2025
Q1 		$173 Hold
9
– – ﹤0.01% 3473
2024
Q4 		$173 Buy
+9
New +$196 ﹤0.01% 3468

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Principal Securities's VRDN Position: Q4 2025 in Review

Principal Securities sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 9 shares — an estimated $194 sold.

Principal Securities first reported a position in VRDN in Q4 2024 and held it in 4 quarters. The position peaked at $194 in Q3 2025. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Principal Securities reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 9 Viridian Therapeutics shares in Q4 2025, an estimated $194.
  • Principal Securities first reported a position in Viridian Therapeutics in Q4 2024 and held it in 4 quarters.
  • Principal Securities's Viridian Therapeutics position peaked at $194 in Q3 2025.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.